Effect of abciximab-coated stent on in-stent intimal hyperplasia in human coronary arteries

Young Joon Hong, Myung Ho Jeong, Weon Kim, Sang Yeob Lim, Sang Hyun Lee, Seo Na Hong, Ju Han Kim, Young Keun Ahn, Jeong Gwan Cho, Jong Chun Park, Dong Lyun Cho, Hoon Kim, Jung Chaee Kang

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

The investigators tested whether abciximab-coated stents prevent neointimal hyperplasia (NIH) formation in coronary de novo lesions. Abciximab-coated stents were compared with control stents. All patients underwent follow-up coronary angiography and intravascular ultrasound (IVUS). All stents were successfully deployed, and patients were discharged home without clinical events. At follow-up coronary angiography, the restenosis rate and late loss were 14% and 0.33 ± 0.28 mm in the abciximab-coated stent group and 28.6% and 0.64 ± 0.32 mm in the control stent group (p = 0.099 and p = 0.014, respectively). At follow-up IVUS, the intrastent luminal area and intrastent NIH area were 5.7 ± 1.6 and 2.0 ± 1.6 mm 2, respectively, in the abciximab-coated stent group and 4.2 ± 0.8 and 3.4 ± 1.7 mm 2, respectively, in the control stent group (p = 0.001 and p = 0.001, respectively). Abciximab-coated stents are feasible and significantly inhibit NIH, with potential therapeutic benefit in preventing stent restenosis.

Original languageEnglish
Pages (from-to)1050-1054
Number of pages5
JournalAmerican Journal of Cardiology
Volume94
Issue number8
DOIs
Publication statusPublished - 2004 Oct 15
Externally publishedYes

Fingerprint

Tunica Intima
Hyperplasia
Stents
Coronary Vessels
Coronary Angiography
abciximab
Control Groups
Research Personnel

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Effect of abciximab-coated stent on in-stent intimal hyperplasia in human coronary arteries. / Hong, Young Joon; Jeong, Myung Ho; Kim, Weon; Lim, Sang Yeob; Lee, Sang Hyun; Hong, Seo Na; Kim, Ju Han; Ahn, Young Keun; Cho, Jeong Gwan; Park, Jong Chun; Cho, Dong Lyun; Kim, Hoon; Kang, Jung Chaee.

In: American Journal of Cardiology, Vol. 94, No. 8, 15.10.2004, p. 1050-1054.

Research output: Contribution to journalArticle

Hong, YJ, Jeong, MH, Kim, W, Lim, SY, Lee, SH, Hong, SN, Kim, JH, Ahn, YK, Cho, JG, Park, JC, Cho, DL, Kim, H & Kang, JC 2004, 'Effect of abciximab-coated stent on in-stent intimal hyperplasia in human coronary arteries', American Journal of Cardiology, vol. 94, no. 8, pp. 1050-1054. https://doi.org/10.1016/j.amjcard.2004.06.066
Hong, Young Joon ; Jeong, Myung Ho ; Kim, Weon ; Lim, Sang Yeob ; Lee, Sang Hyun ; Hong, Seo Na ; Kim, Ju Han ; Ahn, Young Keun ; Cho, Jeong Gwan ; Park, Jong Chun ; Cho, Dong Lyun ; Kim, Hoon ; Kang, Jung Chaee. / Effect of abciximab-coated stent on in-stent intimal hyperplasia in human coronary arteries. In: American Journal of Cardiology. 2004 ; Vol. 94, No. 8. pp. 1050-1054.
@article{92c0183eea07479d81563b576fac76da,
title = "Effect of abciximab-coated stent on in-stent intimal hyperplasia in human coronary arteries",
abstract = "The investigators tested whether abciximab-coated stents prevent neointimal hyperplasia (NIH) formation in coronary de novo lesions. Abciximab-coated stents were compared with control stents. All patients underwent follow-up coronary angiography and intravascular ultrasound (IVUS). All stents were successfully deployed, and patients were discharged home without clinical events. At follow-up coronary angiography, the restenosis rate and late loss were 14{\%} and 0.33 ± 0.28 mm in the abciximab-coated stent group and 28.6{\%} and 0.64 ± 0.32 mm in the control stent group (p = 0.099 and p = 0.014, respectively). At follow-up IVUS, the intrastent luminal area and intrastent NIH area were 5.7 ± 1.6 and 2.0 ± 1.6 mm 2, respectively, in the abciximab-coated stent group and 4.2 ± 0.8 and 3.4 ± 1.7 mm 2, respectively, in the control stent group (p = 0.001 and p = 0.001, respectively). Abciximab-coated stents are feasible and significantly inhibit NIH, with potential therapeutic benefit in preventing stent restenosis.",
author = "Hong, {Young Joon} and Jeong, {Myung Ho} and Weon Kim and Lim, {Sang Yeob} and Lee, {Sang Hyun} and Hong, {Seo Na} and Kim, {Ju Han} and Ahn, {Young Keun} and Cho, {Jeong Gwan} and Park, {Jong Chun} and Cho, {Dong Lyun} and Hoon Kim and Kang, {Jung Chaee}",
year = "2004",
month = "10",
day = "15",
doi = "10.1016/j.amjcard.2004.06.066",
language = "English",
volume = "94",
pages = "1050--1054",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - Effect of abciximab-coated stent on in-stent intimal hyperplasia in human coronary arteries

AU - Hong, Young Joon

AU - Jeong, Myung Ho

AU - Kim, Weon

AU - Lim, Sang Yeob

AU - Lee, Sang Hyun

AU - Hong, Seo Na

AU - Kim, Ju Han

AU - Ahn, Young Keun

AU - Cho, Jeong Gwan

AU - Park, Jong Chun

AU - Cho, Dong Lyun

AU - Kim, Hoon

AU - Kang, Jung Chaee

PY - 2004/10/15

Y1 - 2004/10/15

N2 - The investigators tested whether abciximab-coated stents prevent neointimal hyperplasia (NIH) formation in coronary de novo lesions. Abciximab-coated stents were compared with control stents. All patients underwent follow-up coronary angiography and intravascular ultrasound (IVUS). All stents were successfully deployed, and patients were discharged home without clinical events. At follow-up coronary angiography, the restenosis rate and late loss were 14% and 0.33 ± 0.28 mm in the abciximab-coated stent group and 28.6% and 0.64 ± 0.32 mm in the control stent group (p = 0.099 and p = 0.014, respectively). At follow-up IVUS, the intrastent luminal area and intrastent NIH area were 5.7 ± 1.6 and 2.0 ± 1.6 mm 2, respectively, in the abciximab-coated stent group and 4.2 ± 0.8 and 3.4 ± 1.7 mm 2, respectively, in the control stent group (p = 0.001 and p = 0.001, respectively). Abciximab-coated stents are feasible and significantly inhibit NIH, with potential therapeutic benefit in preventing stent restenosis.

AB - The investigators tested whether abciximab-coated stents prevent neointimal hyperplasia (NIH) formation in coronary de novo lesions. Abciximab-coated stents were compared with control stents. All patients underwent follow-up coronary angiography and intravascular ultrasound (IVUS). All stents were successfully deployed, and patients were discharged home without clinical events. At follow-up coronary angiography, the restenosis rate and late loss were 14% and 0.33 ± 0.28 mm in the abciximab-coated stent group and 28.6% and 0.64 ± 0.32 mm in the control stent group (p = 0.099 and p = 0.014, respectively). At follow-up IVUS, the intrastent luminal area and intrastent NIH area were 5.7 ± 1.6 and 2.0 ± 1.6 mm 2, respectively, in the abciximab-coated stent group and 4.2 ± 0.8 and 3.4 ± 1.7 mm 2, respectively, in the control stent group (p = 0.001 and p = 0.001, respectively). Abciximab-coated stents are feasible and significantly inhibit NIH, with potential therapeutic benefit in preventing stent restenosis.

UR - http://www.scopus.com/inward/record.url?scp=5044230364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=5044230364&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2004.06.066

DO - 10.1016/j.amjcard.2004.06.066

M3 - Article

VL - 94

SP - 1050

EP - 1054

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 8

ER -